College of Nursing and Health Sciences, Flinders University of South Australia, Bedford Park 5042, SA, Australia; The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.
The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia; Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, QLD, Australia.
J Adv Res. 2022 Sep;40:179-196. doi: 10.1016/j.jare.2021.11.013. Epub 2021 Nov 26.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease (COVID-19) triggers the development of numerous pathologies and infection-linked complications and exacerbates existing pathologies in nearly all body systems. Aside from the primarily targeted respiratory organs, adverse SARS-CoV-2 effects were observed in nervous, cardiovascular, gastrointestinal/metabolic, immune, and other systems in COVID-19 survivors. Long-term effects of this viral infection have been recently observed and represent distressing sequelae recognised by the World Health Organisation (WHO) as a distinct clinical entity defined as post-COVID-19 condition. Considering the pandemic is still ongoing, more time is required to confirm post COVID-19 condition diagnosis in the COVID-19 infected cohorts, although many reported post COVID-19 symptoms overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
In this study, COVID-19 clinical presentation and associated post-infection sequelae (post-COVID-19 condition) were reviewed and compared with ME/CFS symptomatology.
The onset, progression, and symptom profile of post COVID-19 condition patients have considerable overlap with ME/CFS. Considering the large scope and range of pro-inflammatory effects of this virus, it is reasonable to expect development of post COVID-19 clinical complications in a proportion of the affected population. There are reports of a later debilitating syndrome onset three months post COVID-19 infection (often described as long-COVID-19), marked by the presence of fatigue, headache, cognitive dysfunction, post-exertional malaise, orthostatic intolerance, and dyspnoea. Acute inflammation, oxidative stress, and increased levels of interleukin-6 (IL-6) and tumor necrosis factor α (TNFα), have been reported in SARS-CoV-2 infected patients. Longitudinal monitoring of post COVID-19 patients is warranted to understand the long-term effects of SARS-CoV-2 infection and the pathomechanism of post COVID-19 condition.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疾病(COVID-19)引发了许多病理学和感染相关并发症的发展,并使几乎所有身体系统中的现有病理学恶化。除了主要靶向的呼吸器官外,COVID-19 幸存者的神经系统、心血管系统、胃肠道/代谢系统、免疫系统和其他系统也观察到了不利的 SARS-CoV-2 影响。这种病毒感染的长期影响最近才被观察到,并代表着世界卫生组织(WHO)所认定的痛苦后遗症,即 COVID-19 后状况。考虑到大流行仍在继续,需要更多时间来确认 COVID-19 感染队列中的 COVID-19 后状况诊断,尽管许多报道的 COVID-19 后症状与肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)重叠。
在这项研究中,回顾了 COVID-19 的临床表现和相关感染后后遗症(COVID-19 后状况),并将其与 ME/CFS 的症状进行了比较。
COVID-19 后状况患者的发病、进展和症状谱与 ME/CFS 有很大重叠。考虑到这种病毒广泛的炎症反应范围和程度,预计在受影响人群中,一部分人会出现 COVID-19 后临床并发症。有报道称,COVID-19 感染后三个月会出现一种衰弱性综合征(常被描述为长 COVID-19),其特征是疲劳、头痛、认知功能障碍、劳累后不适、体位不耐受和呼吸困难。在 SARS-CoV-2 感染患者中,已报道存在急性炎症、氧化应激以及白细胞介素 6(IL-6)和肿瘤坏死因子 α(TNFα)水平升高。有必要对 COVID-19 后患者进行纵向监测,以了解 SARS-CoV-2 感染的长期影响和 COVID-19 后状况的发病机制。